Kathleen K Harnden
2PUBLICATIONS
36CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (2)
Sort by Publication Date:
|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn
|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven
Pageof 1
Frequent Collaborators
2 joint publications
Aditya Bardia
2 joint publications
Joohyuk Sohn
2 joint publications
Philippe Aftimos
1 joint publications
Javier Cortés
1 joint publications
Elgene Lim
1 joint publications
Rinath Jeselsohn
1 joint publications
Cynthia X Ma
1 joint publications
Erika P Hamilton
1 joint publications
Peter A Kaufman
1 joint publications
Luis Manso Sanchez
